NASDAQ:XRAY - DENTSPLY SIRONA Stock Price, Price Target & More

DENTSPLY SIRONA trades on the NASDAQ under the ticker symbol "XRAY."

DENTSPLY SIRONA declared a quarterly dividend on Tuesday, June 26th. Shareholders of record on Friday, September 28th will be paid a dividend of $0.0875 per share on Friday, October 12th. This represents a $0.35 annualized dividend and a yield of 0.79%. The ex-dividend date is Thursday, September 27th. View DENTSPLY SIRONA's Dividend History.

DENTSPLY SIRONA Inc (NASDAQ:XRAY) released its quarterly earnings data on Sunday, May, 6th. The medical instruments supplier reported $0.45 EPS for the quarter, topping analysts' consensus estimates of $0.42 by $0.03. The medical instruments supplier earned $956.10 million during the quarter, compared to analyst estimates of $942.20 million. DENTSPLY SIRONA had a negative net margin of 38.32% and a positive return on equity of 8.63%. The firm's quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.49 EPS. View DENTSPLY SIRONA's Earnings History.

DENTSPLY SIRONA is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for DENTSPLY SIRONA.

DENTSPLY SIRONA updated its FY18 earnings guidance on Monday, May, 7th. The company provided EPS guidance of $2.55-2.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.70.

14 Wall Street analysts have issued 1 year price targets for DENTSPLY SIRONA's shares. Their forecasts range from $52.00 to $75.00. On average, they anticipate DENTSPLY SIRONA's stock price to reach $61.4167 in the next year. This suggests a possible upside of 38.8% from the stock's current price. View Analyst Ratings for DENTSPLY SIRONA.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DENTSPLY SIRONA in the last year. There are currently 5 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to DENTSPLY SIRONA include Straumann (SAUHF), Sartorius (SARTF), Nobel Biocare (NBHGF), Biomerica (BMRA), BIOLASE (BIOL) and Remedent (REMI).

News headlines about XRAY stock have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. DENTSPLY SIRONA earned a media sentiment score of 0.10 on Accern's scale. They also gave media stories about the medical instruments supplier an impact score of 45.96 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

DENTSPLY SIRONA's stock is owned by a number of of institutional and retail investors. Top institutional investors include GENERATION INVESTMENT MANAGEMENT LLP (5.20%), Bank of Montreal Can (0.10%), Stonebridge Capital Management Inc. (0.06%), First National Bank of Omaha (0.05%), Retirement Systems of Alabama (0.05%) and Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%). Company insiders that own DENTSPLY SIRONA stock include Arthur D Kowaloff, Bret W Wise, Christopher T Clark, Donald M Jr Casey, Eric Brandt, Francis J Lunger, James G Mosch, Mark Thierer, Maureen J Macinnis, Michael C Alfano, Michael J Coleman, Nicholas W Alexos, Rainer Berthan and Ulrich Michel. View Institutional Ownership Trends for DENTSPLY SIRONA.

XRAY stock was sold by a variety of institutional investors in the last quarter, including NN Investment Partners Holdings N.V., Clinton Group Inc., Hills Bank & Trust Co., Fjarde AP Fonden Fourth Swedish National Pension Fund, Bath Savings Trust Co, Retirement Systems of Alabama, First National Bank of Omaha and Wendell David Associates Inc.. Company insiders that have sold DENTSPLY SIRONA company stock in the last year include Eric Brandt, Francis J Lunger, Michael C Alfano and Michael J Coleman. View Insider Buying and Selling for DENTSPLY SIRONA.

XRAY stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Stonebridge Capital Management Inc., FormulaFolio Investments LLC, Bank of Montreal Can, Rowland & Co. Investment Counsel ADV, IFM Investors Pty Ltd and DnB Asset Management AS. Company insiders that have bought DENTSPLY SIRONA stock in the last two years include Donald M Jr Casey, Mark Thierer and Nicholas W Alexos. View Insider Buying and Selling for DENTSPLY SIRONA.

Shares of XRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of XRAY stock can currently be purchased for approximately $44.24.

DENTSPLY SIRONA has a market capitalization of $10.17 billion and generates $3.99 billion in revenue each year. The medical instruments supplier earns $-1,550,000,000.00 in net income (profit) each year or $2.66 on an earnings per share basis. DENTSPLY SIRONA employs 16,100 workers across the globe.

DENTSPLY SIRONA's mailing address is 221 WEST PHILADELPHIA STREET, YORK PA, 17401. The medical instruments supplier can be reached via phone at 717-845-7511 or via email at [email protected]